SLS SELLAS Life Sciences Group, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 11, 2026SLS Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
SLS Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 08 Kasım 2019 | 1-for-50 | Ters |
| 02 Ocak 2018 | 1-for-30 | Ters |
| 14 Kasım 2016 | 1-for-20 | Ters |
SELLAS Life Sciences Group, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigating their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | SLS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -55.65Y ort. ≈-4.6 | ≈-4.6 | · | · | |
| F/D (MRQ) | 17.25Y ort. ≈5.3 | ≈5.3 | 4.4 | Aşırı değerli | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -75.05Y ort. ≈-5.8 | ≈-5.8 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 30.95Y ort. ≈10.1 | ≈10.1 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | SLS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| ROA | -54.9%5Y ort. ≈-160.6% | ≈-160.6% | -40.3% | Zayıf | |
| ROE | -55.4%5Y ort. ≈-45.6% | ≈-45.6% | -50.3% | Zayıf | |
| ROIC | -39.9%5Y ort. ≈-177.1% | ≈-177.1% | -39.9% | Aynı seviyede |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | SLS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 18.85Y ort. ≈3.7 | ≈3.7 | 14.8 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 10.25Y ort. ≈3.5 | ≈3.5 | 8.7 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | SLS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue / Employee (Çalışan Başına Gelir) | ≈$0.00 | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 10, 2026 | $-0.05 | $-0.05 | -9.9% |
| 31 Mart 2026 | May 11, 2026 | $-0.05 | $-0.04 | -23.8% |
| 31 Aralık 2025 | $-0.05 | $-0.07 | 23.9% | |
| 30 Eylül 2025 | $-0.06 | $-0.07 | 10.0% | |
| 30 Haziran 2025 | $-0.07 | $-0.08 | 15.9% | |
| 31 Mart 2025 | $-0.07 | $-0.11 | 34.0% | |
| 31 Aralık 2024 | $-0.08 | $-0.11 | 26.2% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.46 | $0.13 | $-0.25 | $0.23 | $1.28 | $1.96 | $1.20 | · | $0.36 | $1.89 | · | · | |
| Revenue / Share | · | · | $0.00 | $0.05 | $0.49 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.26 | $-0.58 | $-1.13 | $-1.23 | $-1.68 | · | · | · | · | · | · | · | |
| Cash / Share | $0.47 | $0.19 | $0.08 | $0.82 | $1.34 | $2.48 | $1.43 | · | $0.40 | $1.19 | · | · | |
| EPS (TTM) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.68 | $0.59 | · | $0.36 | $0.26 | $0.31 | · | $0.25 | $0.05 | $0.17 | · | $-0.13 | $0.17 | $0.46 | · | $0.61 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-0.05 | · | · | · | $-0.10 | · | · | · | $-0.24 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $0.69 | $0.59 | · | $0.35 | $0.25 | $0.31 | · | $0.33 | $0.16 | $0.33 | · | $0.14 | $0.49 | $0.84 | · | $1.04 | |
| EPS (TTM) | $-0.21 | $-0.23 | · | $-0.26 | $-0.30 | $-0.36 | · | $-0.67 | $-0.90 | $-1.08 | · | $-1.44 | $-1.45 | $-1.55 | · | $-2.23 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $1M | |
| Net Income TTM | $-32M | $-29M | · | $-26M | $-26M | $-27M | · | $-32M | $-34M | $-36M | · | $-38M | $-36M | $-36M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -70.3 | -18.4 | · | -6.2 | -7.3 | -3.0 | · | -1.9 | -1.3 | -0.9 | · | -1.1 | -1.1 | -0.9 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.4% | -5.4% | · | -16.2% | -13.7% | -33.3% | · | -53.6% | -75.6% | -106.9% | · | -87.8% | -92.4% | -108.4% | · | -110.4% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | · | · | $0 | $1M | $8M |
| Faaliyet Kâr Marjı % | · | · | · | -4195.0% | -332.8% |
| Net Gelir | $-27M | $-31M | $-37M | $-41M | $-21M |
| Seyreltilmiş Hisse Başı Kâr | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| Cari Oran | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
Bu beyanı oluşturmak için henüz yeterli temel verisi yok.
Kurumsal Sahipler (13F) 234 dosya · $1.5B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 85 (+18 önceki Ç'ye göre) | 19 (+4 önceki Ç'ye göre) | 84 (+25 önceki Ç'ye göre) | 31 (+8 önceki Ç'ye göre) | +33.3M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $222.437.657 | 15.070.302 | 14,45% | Hisse senetleri |
| STATE STREET CORP | $191.829.196 | 12.996.558 | 12,47% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $121.417.310 | 8.226.105 | 7,89% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105.640.272 | 7.157.200 | 6,86% | Alım opsiyonu |
| GEODE CAPITAL MANAGEMENT, LLC | $72.107.010 | 4.884.175 | 4,69% | Hisse senetleri |
| Anson Funds Management LP | $66.420.000 | 4.500.000 | 4,32% | Hisse senetleri |
| CITADEL ADVISORS LLC | $64.157.292 | 4.346.700 | 4,17% | Alım opsiyonu |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61.832.592 | 4.189.200 | 4,02% | Satım opsiyonu |
| CITADEL ADVISORS LLC | $33.333.984 | 2.258.400 | 2,17% | Satım opsiyonu |
| VANGUARD GROUP INC | $31.922.098 | 8.467.400 | 2,07% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31.897.821 | 2.161.099 | 2,07% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30.266.812 | 2.050.597 | 1,97% | Hisse senetleri |
| JONES FINANCIAL COMPANIES LLLP | $28.553.511 | 2.304.561 | 1,86% | Hisse senetleri |
| Anson Funds Management LP | $27.245.484 | 1.845.900 | 1,77% | Satım opsiyonu |
| NORTHERN TRUST CORP | $23.910.138 | 1.619.928 | 1,55% | Hisse senetleri |
| PERCEPTIVE ADVISORS LLC | $22.140.000 | 1.500.000 | 1,44% | Satım opsiyonu |
| VANGUARD FIDUCIARY TRUST CO | $19.707.050 | 1.335.166 | 1,28% | Hisse senetleri |
| UBS Group AG | $18.490.693 | 1.252.757 | 1,20% | Hisse senetleri |
| MORGAN STANLEY | $18.247.211 | 1.236.261 | 1,19% | Hisse senetleri |
| Sio Capital Management, LLC | $18.165.132 | 1.230.700 | 1,18% | Satım opsiyonu |
| BNP PARIBAS FINANCIAL MARKETS | $15.823.045 | 1.072.022 | 1,03% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $15.424.200 | 10.450 | 1,00% | Satım opsiyonu |
| MILLENNIUM MANAGEMENT LLC | $13.372.560 | 906.000 | 0,87% | Satım opsiyonu |
| BARCLAYS PLC | $11.831.616 | 801.600 | 0,77% | Satım opsiyonu |
| Anson Funds Management LP | $11.808.000 | 800.000 | 0,77% | Alım opsiyonu |
| BANK OF AMERICA CORP /DE/ | $11.630.128 | 787.949 | 0,76% | Hisse senetleri |
| JANE STREET GROUP, LLC | $11.058.192 | 749.200 | 0,72% | Alım opsiyonu |
| WELLINGTON MANAGEMENT GROUP LLP | $8.816.282 | 597.309 | 0,57% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $8.635.117 | 585.035 | 0,56% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8.339.518 | 565.008 | 0,54% | Hisse senetleri |
| Bank of New York Mellon Corp | $7.823.173 | 530.025 | 0,51% | Hisse senetleri |
| JANE STREET GROUP, LLC | $7.504.412 | 508.429 | 0,49% | Hisse senetleri |
| Balyasny Asset Management L.P. | $7.380.000 | 500.000 | 0,48% | Satım opsiyonu |
| LMR Partners LLP | $6.642.000 | 450.000 | 0,43% | Satım opsiyonu |
| NOMURA HOLDINGS INC | $6.273.000 | 425.000 | 0,41% | Alım opsiyonu |
| Nuveen, LLC | $6.180.440 | 418.729 | 0,40% | Hisse senetleri |
| DIADEMA PARTNERS LP | $5.904.000 | 400.000 | 0,38% | Alım opsiyonu |
| Invesco Ltd. | $5.540.049 | 375.342 | 0,36% | Hisse senetleri |
| Swiss National Bank | $5.319.504 | 360.400 | 0,35% | Hisse senetleri |
| XTX Topco Ltd | $5.300.168 | 359.090 | 0,34% | Hisse senetleri |
| Ikarian Capital, LLC | $5.235.372 | 354.700 | 0,34% | Satım opsiyonu |
| WELLS FARGO & COMPANY/MN | $4.853.368 | 328.819 | 0,32% | Hisse senetleri |
| CITIGROUP INC | $4.820.483 | 326.591 | 0,31% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $4.580.973 | 310.364 | 0,30% | Hisse senetleri |
| DAGCO, INC. | $4.351.740 | 1.028.780 | 0,28% | Hisse senetleri |
| Everhart Financial Group, Inc. | $4.251.146 | 288.018 | 0,28% | Hisse senetleri |
| Rafferty Asset Management, LLC | $3.540.806 | 239.892 | 0,23% | Hisse senetleri |
| RHUMBLINE ADVISERS | $3.400.726 | 230.402 | 0,22% | Hisse senetleri |
| Walleye Capital LLC | $3.377.088 | 228.800 | 0,22% | Satım opsiyonu |
| TUDOR INVESTMENT CORP ET AL | $3.087.792 | 209.200 | 0,20% | Satım opsiyonu |
Aktivistler ve %5+ sahipler 2 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 başvurular | 10 Ekim 2018 | · | İlk başvuru | · | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 08 Ocak 2018 | · | İlk başvuru | M&A / satış | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 43 içeriden öğrenenler · 17 yöneticiler · 9 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16 Haziran 2026 A | 1.759.183 | 0 | 0 | $0 |
| Mark W. Schwartz | President & CEO | 01 Temmuz 2016 J | 439.978 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15 Mart 2011 A | 92.994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 07 Ocak 2026 A | 554.327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20 Nisan 2018 A | · | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13 Nisan 2011 A | 379.294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15 Ocak 2009 A | · | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 07 Ocak 2026 A | 557.805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22 Ocak 2024 A | 40.918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22 Ocak 2024 A | 117.225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14 Mart 2019 A | · | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13 Mart 2018 A | · | 0 | 0 | $0 |
| Kwang Lee | Principal Accounting Officer | 07 Aralık 2011 P | 5.000 | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15 Mart 2011 A | 14.065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15 Mart 2011 A | 41.083 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15 Nisan 2010 A | 5.750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31 Mart 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | Yönetim kurulu üyesi | 07 Ocak 2026 A | 154.400 | 1 | 0 | $100.806 |
| John Varian | Yönetim kurulu üyesi | 07 Ocak 2026 A | 72.900 | 0 | 0 | $0 |
| Jane Wasman | Yönetim kurulu üyesi | 07 Ocak 2026 A | 92.900 | 0 | 0 | $0 |
| David A Scheinberg | Yönetim kurulu üyesi | 07 Ocak 2026 A | 73.082 | 0 | 0 | $0 |
| Robert L Van Nostrand | Yönetim kurulu üyesi | 07 Ocak 2026 A | 82.900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | Yönetim kurulu üyesi | 14 Mart 2019 A | · | 0 | 0 | $0 |
| Fabio Lopez | Yönetim kurulu üyesi | 12 Haziran 2018 A | · | 0 | 0 | $0 |
| Irving M. Einhorn | · | 10 Ekim 2017 A | 34.690 | 0 | 0 | $0 |
| William Ashton | · | 10 Ekim 2017 A | 38.154 | 0 | 0 | $0 |
| Richard Chin | · | 10 Ekim 2017 A | 31.339 | 0 | 0 | $0 |
| Rudolph Nisi | · | 10 Ekim 2017 A | 42.918 | 0 | 0 | $0 |
| Sanford Hillsberg | · | 10 Ekim 2017 A | 56.950 | 0 | 0 | $0 |
| Mary Ann Gray | · | 10 Ekim 2017 A | 39.167 | 0 | 0 | $0 |
| Stephen S Galliker | · | 10 Ekim 2017 A | 36.039 | 0 | 0 | $0 |
| Thomas J Knapp | · | 06 Şubat 2017 A | · | 0 | 0 | $0 |
| Bijan Nejadnik | · | 17 Ocak 2017 A | 8.503 | 0 | 0 | $0 |
| Ryan Dunlap | · | 01 Haziran 2016 M | 18.702 | 0 | 0 | $0 |
| Steven A Kriegsman | · | 19 Haziran 2015 A | 5.000 | 0 | 0 | $0 |
| Margaret Kivinski | · | 16 Ocak 2015 A | · | 0 | 0 | $0 |
| Brian L Hamilton | · | 30 Haziran 2014 J | 2.461 | 0 | 0 | $0 |
| Mark J Ahn | · | 30 Haziran 2014 A | 116.225 | 0 | 0 | $0 |
| Rosemary Mazanet | · | 29 Ocak 2013 A | · | 0 | 0 | $0 |
| Anastasia Khvorova | · | 24 Eylül 2011 A | 137.482 | 0 | 0 | $0 |
| Pamela Pavco | · | 24 Eylül 2011 A | 44.940 | 0 | 0 | $0 |
| CYTRX CORP | · | 29 Aralık 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | · | 15 Ocak 2009 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 26 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,86% | 285.002 SH | 01 Ekim 2026 | Günlük |
| BBC · ETFis Series Trust I | 0,86% | 39.695 NS | 31 Temmuz 2026 | N-PORT |
| IWC · iShares Trust | 0,60% | 640.712 SH | 11 Eylül 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,59% | 293.250 NS | 31 Temmuz 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,23% | 316.525 SH | 19 Ağustos 2026 | Günlük |
| ICOP · iShares Trust | 0,21% | 131.527 SH | 11 Eylül 2026 | Günlük |
| IWO · iShares Trust | 0,17% | 1.775.566 SH | 11 Eylül 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,17% | 4.006 NS | 31 Temmuz 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,16% | 202.339 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,08% | 4.838.243 SH | 11 Eylül 2026 | Günlük |
| ISCG · iShares Trust | 0,08% | 57.697 SH | 11 Eylül 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,08% | 1.086.285 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,06% | 90.355 NS | 31 Temmuz 2026 | N-PORT |
| ESML · iShares Trust | 0,05% | 105.699 SH | 11 Eylül 2026 | Günlük |
| PICK · iShares, Inc. | 0,05% | 147.515 SH | 11 Eylül 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,04% | 540.244 SH | 19 Ağustos 2026 | Günlük |
| ISCF · iShares Trust | 0,04% | 30.200 SH | 11 Eylül 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.134.285 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,03% | 17.066 SH | 11 Eylül 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 85.332 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 273.788 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 44.399 SH | 11 Eylül 2026 | Günlük |
| IXUS · iShares Trust | 0,00% | 98.316 SH | 11 Eylül 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.908.560 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 15.706 SH | 19 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 8.283 SH | 11 Eylül 2026 | Günlük |
SLS Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
12 Aylık Fiyat Hedefi
2 analist · 2026-10-02Ortalama hedef $32.50 +176,8%
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | · | · | -55.4% | · |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | · |
| CLDX | $1.81B | -7.0 | -78.0% | -16748.0% | -43.8% | · |
| IRON | $3.01B | -13.2 | · | · | -31.3% | · |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | · |
| IMNM | $2.43B | -8.8 | -23.2% | -3060.0% | -47.0% | · |
| VRDN | $3.17B | -7.7 | 23359.9% | -483.6% | -55.4% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.